|
| Authors | MRI scan | Study design | Cases | Mean PSA | Reference standard | T2WI | DCE | MRSI | DWI | Combined techniques |
|
| Sala et al. [12] | PAC + ERC 1.5-T | Prospective | 45 | 3.57 ng/dL | Whole-mount RP section | Se 36–76%
Spe 65–81%
0.61–0.75 | | | | |
|
| Westphalen et al. [13] | PAC + ERC 1.5-T | Retrospective | 59 | | TRUS biopsy | Se 62–74%
Sp 64–68%
PPV 70–80%
NPV 50–70%
Acc 63–71% | | | | |
|
|
Rouvière et al. [14] | PAC 1.5-T | Prospective | 22 | 6.36 ng/dL | TRUS biopsy | Se 26–44%
Sp 64–86%
PPV 47–63%
NPV 61–69%
Acc 54–60% | Se 70–74%
Sp 73–85%
PPV 68–78%
NPV 78-79%
Acc 73–79% | | | |
|
| Haider et al. [15] | PAC 1.5-T | Prospective | 33 | 2.1 ng/dL | TRUS biopsy | Se 38%
Sp 80%
PPV 24%
NPV 88%
Acc 74% | Se 72%
Sp 85%
PPV 46%
NPV 95%
Acc 83% | | | |
|
| Kara et al. [16] | PAC 1.5-T | Retrospective | 20 | | TRUS biopsy | Se 86.7%
Sp 100%
PPV 100%
NPV 71%
Acc 90% | Se 93.3%
Sp 100%
PPV 100%
NPV 83.3%
Acc 95% | | | |
|
| Menard et al. [17] | | Prospective | 35 | | TRUS biopsy | | | Se 88.9%
Sp 92%
PPV 91.7%
Acc 91.4% | | |
|
| Coakley et al. [18] | PAC + ERC 1.5-T | Retrospective | 21 | 2.3 ng/dL | TRUS biopsy | 0.49–0.51 | | Se 89%
Sp 82%
PPV 64%
NPV 96%
0.81 | | |
|
| Pucar et al. [19] | PAC + ERC 1.5-T | Prospective | 9 | 3.7 ng/dL | Whole-mount RP section | Se 68%
Sp 96% | | Se 77%
Sp 78% | | |
|
| Westphalen et al. [20] | PAC + ERC 1.5-T | Retrospective | 64 | 2.6 ng/dL | TRUS biopsy | 0.67 | | T2WI + MRS:
0.79 | | |
|
| Wu et al. [9] | | Metanalysis | | | | Se 74%
Spe 65%
| Se 90%
Spe 81%
| | | MRSI + DCE:
Se 90%
Spe 90% |
|
| Tamada et al. [21] | PAC 1.5-T | Retrospective | 16 | 7.42 ng/dL | TRUS biopsy | Se 27%
Sp 99%
PPV 86%
NPV 87%
Acc 87% | Se 50%
Sp 98%
PPV 85%
NPV 90%
Acc 90% | | Se 68%
Sp 95%
PPV 75%
NPV 94%
Acc 91% | T2WI + DCE + DWI:
Se 77%
Sp 92%
PPV 68%
NPV 95%
Acc 90% |
|
| Kim et al. [22] | PAC 3.0-T | Prospective | 36 | 3.44 ng/dL | TRUS biopsy | Se 25%
Sp 92%
PPV 57%
NPV 74%
0.612 | | | | T2WI + DWI:
Se 62%
Sp 97%
PPV 91%
NPV 81%
0.879 |
|
| Morgan et al. [23] | ERC 1.5-T | Retrospective | 24 | | TRUS biopsy | | | | Se 93.8%
Sp 75%
PPV 8.2%
NPV 85.7% | |
|
| Hara et al. [24] | PAC 1.5-T | Retrospective | 10 | 4.44 ng/dL | TRUS biopsy | | | | Se 69%
Sp 91%
PPV 37%
NPV 97%
Acc 89% | |
|
| Arumainayagam et al. [25] | PAC 1.5-T | Retrospective | 13 | | TRUS biopsy | | | | | T2WI + DCE + DWI:
0.86–0.93 |
|
| Westphalen et al. [26] | PAC + ERC 3.0-T | Retrospective | 26 | 2.5 ng/dL | TRUS biopsy | 0.616
| | 0.830
| 0.755
| T2WI + MRS + DWI:
0.869
MRS + DWI:
0.863
T2WI + MRS:
0.841
T2WI + DWI:
0.774 |
|
| Kim et al. [27] | PAC 3.0-T | Retrospective | 24 | 2.76 ng/dL | TRUS biopsy | Se 27%
Sp 80%
PPV 32%
NPV 76%
Acc 67%
0.594 | Se 49%
Sp 92%
PPV 67%
NPV 84%
Acc 81%
0.737 | | Se 49%
Sp 93%
PPV 72%
NPV 84%
Acc 82%
0.782 | DCE + DWI:
Se 59%
Sp 91%
PPV 69%
NPV 87%
Acc 83%
0.863 |
|
| Akin et al. [28] | PAC + ERC 1.5-T | Retrospective | 24 | 1.63 ng/dL | TRUS biopsy | Se 13–81%
Sp 25–88%
0.53–0.64 | | | | T2WI + DCE + DWI:
Se 81–94%
Sp 75–100%
0.86–0.95 |
|
| Donati et al. [29] | PAC + ERC 1.5 or 3.0-T | Retrospective | 53 | | TRUS biopsy | Se 54–66%
Sp 39–61%
PPV 63–77%
NPV 30–48%
0.46–0.632 | | | | T2WI + DCE:
Se 60–63%
Sp 56–89%
PPV 73–91%
NPV 44–53%
0.601–0.830
T2WI + DWI:
Se 54–83%
Sp 89–94%
PPV 93–95%
NPV 52–73%
0.812–0.863
T2WI + DCE + DWI:
Se 49–71%
Sp 94%
PPV 94–96%
NPV 49–63%
0.722–0.879 |
|
| Roy et al. [11] | PAC + ERC 3.0-T | Retrospective | 32 | 3.6 ng/dL | TRUS biopsy | Se 74% | Se 94% | Se 74% | Se 94% | T2WI + DCE: Se 91%
T2WI + DWI + DCE:
Se 100%
T2WI + DWI + DCE + MRS:
Se 76%
T2WI + DWI: Se 94%
T2WI + MRS: 44% |
|
